DHR earnings call: guidance, demand and margins丹纳赫公司 (DHR) 电话会要点：指引、需求与利润率
Danaher Corporation Q2 2026 Earnings Follow-Up Analysis
1. Actual vs Consensus: Per the July 21, 2026 official earnings release and concurrent conference call transcript, adjusted diluted EPS came in at $1.94, beating the consensus estimate of $1.84 by 5.4%. Total revenue hit $6.3B, exceeding the $6.1B consensus by 2.6%, representing 5.3% year-over-year growth.
2. Revenue Quality and Profitability: Gross margin was 57.6%, with operating income of $1.1B and an 18.0% operating margin, though operating income fell 16.1% year-over-year. EBIT and EBITDA both landed at $1.1B, with an 18.0% margin for both metrics. Net income was $870M, with a 13.9% net margin, and GAAP diluted EPS was $1.23.
3. Cash Flow and Capital Position: Quarterly operating cash flow was $1.5B, capex totaled $269M, and free cash flow hit $1.3B. First-half cumulative free cash flow reached $2.4B, with a 124% free cash flow-to-net income conversion rate. Ending cash reserves were $4.3B, total debt $26.6B, and net debt $22.2B.
4. Guidance: Management raised full-year adjusted EPS guidance to a range of $8.45-$8.60, up from previously undisclosed guidance levels. The increase reflects stronger-than-expected Q2 performance and the early close of the Masimo acquisition, with a conservative buffer built in for market uncertainty. Per the transcript, core ex-respiratory revenue is expected to hit ~5% in Q3, with the respiratory revenue headwind fully fading in Q4.
5. GAAP vs Non-GAAP: Official materials disclose GAAP diluted EPS of $1.23 and adjusted EPS of $1.94, but no detailed reconciliation between the two metrics was provided.
6. Management Commentary: Core ex-respiratory revenue grew 4.5% year-over-year, accelerating 150 bps from Q1. Life sciences delivered strong results, bioprocessing saw mid-teens order growth but delayed shipments to future quarters, diagnostics benefited from Alzheimer's test approvals, the Masimo acquisition closed early and earned an FDA 510(k) clearance for an AI respiratory detection tool, and the Leica Biosystems acquisition of StatLab is pending regulatory approval with an expected Q4 2026 close.
7. Investor Watch Items: First, the impact of delayed bioprocessing shipments from a small set of large customers on full-year growth, and whether those shipments will reverse in future quarters. Second, whether the full-year respiratory revenue drag aligns with management's stated ~$1.6B target. Third, the integration progress and synergy realization from the Masimo and StatLab acquisitions.
丹纳赫公司2026年第二季度财报跟进分析
1. 业绩超预期：根据2026年7月21日发布的官方财报及同期电话会议内容，公司二季度调整后摊薄每股收益（EPS）为1.94美元，超出市场预期的1.84美元，超出幅度5.4%；总营收达63亿美元，超出市场预期的61亿美元，超出幅度2.6%，同比增长5.3%。
2. 营收质量与盈利能力：季度毛利率为57.6%，营业利润11亿美元，营业利润率18.0%，但营业利润同比下滑16.1%；EBIT与EBITDA均为11亿美元，利润率均为18.0%；净利润8.7亿美元，净利润率13.9%，GAAP摊薄EPS为1.23美元。
3. 现金流与资本状况：季度经营现金流15亿美元，资本支出2.69亿美元，自由现金流13亿美元；上半年累计自由现金流24亿美元，自由现金流对净利润转化率达124%。期末现金储备43亿美元，总债务26.6亿美元，净债务22.2亿美元。
4. 业绩指引：管理层上调全年调整后EPS指引至8.45-8.60美元，此前未披露具体指引范围。此次上调源于二季度业绩超预期、Masimo收购提前完成带来的收益，同时预留了一定保守缓冲以应对市场不确定性。根据电话会议发言，剔除呼吸道业务的核心营收Q3预计约5%，Q4将摆脱呼吸道业务的同比拖累。
5. GAAP与非GAAP业绩：官方披露GAAP摊薄EPS为1.23美元，调整后EPS为1.94美元，但未公开两者的具体调节细节。
6. 管理层评论：剔除呼吸道业务的核心营收同比增长4.5%，较一季度加速150个基点；生命科学业务表现强劲，生物工艺订单增长中双位数但部分大客户出货延迟至未来季度；诊断业务因阿尔茨海默病检测产品获批实现稳健增长；Masimo收购提前完成并已获得AI辅助呼吸抑制检测产品的FDA 510(k)批准，Leica收购StatLab的交易待监管审批，预计2026年底完成。
7. 投资者关注事项：一是生物工艺业务部分大客户出货延迟对全年增速的影响，需关注后续季度是否回流；二是呼吸道业务全年营收拖累幅度是否符合管理层披露的16亿美元左右目标；三是两项收购的整合进度与协同效应兑现情况。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。